MCID: UTR033
MIFTS: 44

Uterine Corpus Cancer

Categories: Cancer diseases, Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Uterine Corpus Cancer

MalaCards integrated aliases for Uterine Corpus Cancer:

Name: Uterine Corpus Cancer 11 14 16 71
Malignant Uterine Corpus Neoplasm 71
Corpus Uteri Cancer 11

Classifications:



External Ids:

Disease Ontology 11 DOID:9460
ICD9CM 34 182
NCIt 49 C3556
SNOMED-CT 68 93718007
ICD10 31 C54 C54.9
UMLS 71 C0153574 C1883486

Summaries for Uterine Corpus Cancer

Disease Ontology: 11 A uterine cancer that is located in the uterine corpus.

MalaCards based summary: Uterine Corpus Cancer, also known as malignant uterine corpus neoplasm, is related to endometrial cancer and uterine corpus endometrial carcinoma. An important gene associated with Uterine Corpus Cancer is H2AC18 (H2A Clustered Histone 18), and among its related pathways/superpathways are Endometrial cancer and Development EGFR signaling pathway. The drugs Doxorubicin and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include uterine corpus, breast and ovary, and related phenotypes are Increased shRNA abundance (Z-score > 2) and neoplasm

Related Diseases for Uterine Corpus Cancer

Diseases related to Uterine Corpus Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 326)
# Related Disease Score Top Affiliating Genes
1 endometrial cancer 32.3 TP53 PTEN PIK3CA MIR200C HRAS H2AC18
2 uterine corpus endometrial carcinoma 32.3 TP53 PTEN PPP2R1A PIK3CA ARID1A
3 uterine body mixed cancer 32.0 U2AF1 TP53 SLC25A16 PTEN PPP2R1A POLE
4 endometrial serous adenocarcinoma 31.9 TP53 PTEN PPP2R1A POLE PIK3CA MIR34C
5 adenocarcinoma 30.7 TP53 PTEN PIK3CA HRAS ERBB2
6 endometriosis 30.7 TP53 PTEN MIR34C MIR200C
7 papillary serous adenocarcinoma 30.6 TP53 HRAS ERBB2
8 bladder cancer 30.5 TP53 PTEN PIK3CA MIR10B HRAS H2AC18
9 cervical cancer 30.4 U2AF1 TP53 PTEN PIK3CA MIR101-1 HRAS
10 serous cystadenocarcinoma 30.3 TP53 PTEN PPP2R1A POLE PIK3CA HRAS
11 ovarian cancer 30.1 TP53 PTEN PPP2R1A PIK3CA MIR34C MIR34B
12 uterine corpus sarcoma 11.2
13 mixed endometrial stromal and smooth muscle tumor 11.2
14 cystadenocarcinoma 10.5 TP53 PTEN ARID1A
15 high-grade astrocytoma 10.5 TP53 PTEN
16 esophagus small cell carcinoma 10.5 PIK3CA ERBB2
17 anal squamous cell carcinoma 10.5 TP53 PIK3CA H2AC18
18 familial ovarian cancer 10.5 TP53 POLE
19 wolffian duct adenocarcinoma 10.5 U2AF1 PIK3CA
20 apocrine adenocarcinoma 10.5 TP53 PIK3CA ERBB2
21 lung oat cell carcinoma 10.5 TP53 PTEN PIK3CA
22 vaginal carcinosarcoma 10.5 TP53 PIK3CA HRAS
23 intraductal breast benign neoplasm 10.5 TP53 PIK3CA ERBB2
24 breast benign neoplasm 10.5 TP53 PIK3CA ERBB2
25 peritoneum cancer 10.5 TP53 H2AC18 ERBB2
26 apocrine adenosis of breast 10.5 TP53 ERBB2
27 t-cell prolymphocytic leukemia 10.5 TP53 MIR200C H2AC18
28 esophagus verrucous carcinoma 10.5 TP53 PIK3CA
29 diffuse astrocytoma 10.5 TP53 PTEN H2AC18
30 mixed glioma 10.5 TP53 SIGLEC5 PTEN
31 acute erythroid leukemia 10.5 U2AF1 TP53 H2AC18
32 synchronous bilateral breast carcinoma 10.5 TP53 PTEN ERBB2
33 splenic disease 10.5 U2AF1 SIGLEC5 H2AC18
34 keratinizing squamous cell carcinoma 10.5 TP53 PIK3CA HRAS
35 adenocarcinoma in situ 10.5 U2AF1 TP53 HRAS
36 papillary adenofibroma 10.5 PTEN POLE ARID1A
37 thoracic benign neoplasm 10.5 TP53 PIK3CA ERBB2
38 blood protein disease 10.5 U2AF1 TP53 H2AC18
39 childhood medulloblastoma 10.5 TP53 H2AC18 ERBB2
40 vulva squamous cell carcinoma 10.5 TP53 PIK3CA HRAS
41 fallopian tube disease 10.5 TP53 SIGLEC5 H2AC18 ERBB2
42 ovarian clear cell adenocarcinoma 10.5 TP53 PIK3CA H2AC18 ARID1A
43 gallbladder adenocarcinoma 10.5 TP53 HRAS ERBB2
44 adrenal cortex disease 10.5 TP53 MIR139 MIR101-1 H2AC18
45 lung large cell carcinoma 10.5 TP53 HRAS H2AC18
46 glioma 10.5 TP53 PTEN PIK3CA MIR10B
47 thyroid tumor 10.5 PTEN PIK3CA HRAS
48 vaginal cancer 10.5 TP53 PTEN HRAS
49 clear cell adenofibroma 10.5 PIK3CA ARID1A
50 mucosal melanoma 10.4 U2AF1 PTEN HRAS

Graphical network of the top 20 diseases related to Uterine Corpus Cancer:



Diseases related to Uterine Corpus Cancer

Symptoms & Phenotypes for Uterine Corpus Cancer

GenomeRNAi Phenotypes related to Uterine Corpus Cancer according to GeneCards Suite gene sharing:

25 (show all 29)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-1 10.15 POLE
2 Increased shRNA abundance (Z-score > 2) GR00366-A-123 10.15 POLE
3 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.15 PTEN
4 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.15 PTEN
5 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.15 ERBB2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.15 ERBB2 POLE PTEN ARID1A
7 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.15 ARID1A
8 Increased shRNA abundance (Z-score > 2) GR00366-A-186 10.15 ARID1A
9 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.15 ARID1A
10 Increased shRNA abundance (Z-score > 2) GR00366-A-196 10.15 HRAS
11 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.15 POLE
12 Increased shRNA abundance (Z-score > 2) GR00366-A-207 10.15 ERBB2 POLE
13 Increased shRNA abundance (Z-score > 2) GR00366-A-213 10.15 ARID1A
14 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.15 PTEN
15 Increased shRNA abundance (Z-score > 2) GR00366-A-28 10.15 HRAS
16 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.15 ERBB2 POLE
17 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.15 PTEN
18 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.15 ARID1A
19 Increased shRNA abundance (Z-score > 2) GR00366-A-60 10.15 ERBB2
20 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.15 ERBB2 POLE PTEN
21 Increased shRNA abundance (Z-score > 2) GR00366-A-66 10.15 PTEN
22 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.15 ARID1A
23 Increased shRNA abundance (Z-score > 2) GR00366-A-82 10.15 H2AC18
24 Increased shRNA abundance (Z-score > 2) GR00366-A-83 10.15 HRAS
25 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.15 ERBB2 POLE
26 Increased shRNA abundance (Z-score > 2) GR00366-A-87 10.15 ERBB2 HRAS POLE PTEN
27 Increased shRNA abundance (Z-score > 2) GR00366-A-91 10.15 POLE
28 Increased shRNA abundance (Z-score > 2) GR00366-A-93 10.15 PTEN
29 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.15 H2AC18

MGI Mouse Phenotypes related to Uterine Corpus Cancer:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.32 ARID1A ERBB2 HRAS MIR139 PIK3CA POLE

Drugs & Therapeutics for Uterine Corpus Cancer

Drugs for Uterine Corpus Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 158)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
2
Lenograstim Approved, Investigational Phase 3 135968-09-1
3
Pembrolizumab Approved Phase 3 1374853-91-4 254741536
4
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
5
Cisplatin Approved Phase 3 15663-27-1 2767 5702198 441203
6
Carboplatin Approved Phase 3 41575-94-4 10339178 38904
7
Metformin Approved Phase 2, Phase 3 1115-70-4, 657-24-9 4091
8 Immunologic Factors Phase 3
9 Antibiotics, Antitubercular Phase 3
10 Liposomal doxorubicin Phase 3
11 Adjuvants, Immunologic Phase 3
12 Antineoplastic Agents, Immunological Phase 3
13 Albumin-Bound Paclitaxel Phase 3
14 Antimitotic Agents Phase 3
15 Tubulin Modulators Phase 3
16 Hypoglycemic Agents Phase 2, Phase 3
17
Fulvestrant Approved, Investigational Phase 2 129453-61-8 17756771 104741
18
Sodium citrate Approved, Investigational Phase 2 68-04-2 23431961
19
Tamoxifen Approved Phase 2 10540-29-1, 54965-24-1 2733526
20
Medroxyprogesterone acetate Approved, Investigational Phase 2 520-85-4, 71-58-9 6279 10631
21
Bupropion Approved Phase 2 31677-93-7, 34841-39-9, 34911-55-2 444
22
Dopamine Approved Phase 2 62-31-7, 51-61-6 681
23
Trastuzumab Approved, Investigational Phase 2 180288-69-1
24
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
25
Letrozole Approved, Investigational Phase 2 112809-51-5 3902
26
Durvalumab Approved, Investigational Phase 2 1428935-60-7
27
Palbociclib Approved, Investigational Phase 2 571190-30-2 5330286
28
Mebendazole Approved, Vet_approved Phase 2 31431-39-7 4030
29
Piperazine Approved, Vet_approved Phase 2 110-85-0 4837
30
Sunitinib Approved, Investigational Phase 2 557795-19-4 5329102
31
Racepinephrine Approved, Vet_approved Phase 2 51-43-4, 329-65-7 838 5816
32
Afatinib Approved Phase 2 439081-18-2, 850140-72-6 53445376 10184653
33
Adenosine Approved, Investigational Phase 2 58-61-7 60961
34
Trametinib Approved Phase 2 871700-17-3 11707110
35
Pertuzumab Approved Phase 2 380610-27-5
36
Dabrafenib Approved, Investigational Phase 2 1195765-45-7 44462760
37
Osimertinib Approved Phase 2 1421373-65-0 71496458
38
Crizotinib Approved, Investigational Phase 2 877399-52-5 11626560
39
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
40
Bevacizumab Approved, Investigational Phase 2 216974-75-3 135329020
41
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
42
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
43
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
44
Levonorgestrel Approved, Investigational Phase 2 797-63-7 13109
45
Olaparib Approved Phase 1, Phase 2 763113-22-0 23725625
46
Nivolumab Approved Phase 2 946414-94-4
47
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
48
Megestrol acetate Approved, Investigational, Vet_approved Phase 2 595-33-5 11683
49
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
50
D-Tyrosine Approved, Experimental, Investigational, Nutraceutical Phase 2 133585-56-5, 60-18-4, 556-02-5 1153 6057

Interventional clinical trials:

(show top 50) (show all 80)
# Name Status NCT ID Phase Drugs
1 A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients With High Risk, Early Stage Endometrial Carcinoma Unknown status NCT00807768 Phase 3 Carboplatin;Paclitaxel
2 Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF Versus Carboplatin/Paclitaxel in Patients With Stage III &Amp; IV or Recurrent Endometrial Cancer Completed NCT00063999 Phase 3 Carboplatin;Cisplatin;Doxorubicin Hydrochloride;Paclitaxel
3 A Phase III Randomized Clinical Trial of Laparoscopic Pelvic and Para-Aortic Node Sampling With Vaginal Hysterectomy and BSO Versus Open Laparotomy With Pelvic and Para-Aortic Node Sampling and Abdominal Hysterectomy and BSO in Endometrial Adenocarcinoma and Uterine Sarcoma, Clinical Stage I, IIA, Grade I, II, III Completed NCT00002706 Phase 3
4 A Randomized Phase III Study of Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation Followed by Cisplatin and Doxorubicin or Cisplatin, Doxorubicin and Paclitaxel for Advanced Endometrial Carcinoma Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
5 A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer Active, not recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
6 A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma Active, not recruiting NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
7 A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer Active, not recruiting NCT04214067 Phase 3
8 A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer Active, not recruiting NCT03914612 Phase 3 Carboplatin;Paclitaxel
9 Short Course Adjuvant Vaginal Cuff Brachytherapy (VCB) in Early Endometrial Cancer Compared to Standard of Care (SAVE) Active, not recruiting NCT03422198 Phase 3
10 Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Vs. Sandwich Therapy of Carboplatin and Paclitaxel Followed by Tumor Volume Directed Irradiation Then Further Carboplatin and Paclitaxel Active, not recruiting NCT02501954 Phase 3 Cisplatin;Carboplatin;Paclitaxel
11 A Prospective Randomized Single Blind Phase III Trial Comparing Flexitouch Home Maintenance Therapy to Standard Home Maintenance Therapy for Lower Extremity Lymphedema Resulting From Treatment of Gynecologic Malignancy Terminated NCT00577317 Phase 3
12 Phase II Study of Faslodex ? in Recurrent/Metastatic Endometrial Carcinoma Unknown status NCT00006903 Phase 2 Fulvestrant
13 A Phase II Study of Postoperative Intensity Modulated Radiation Therapy (IMRT) With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer Completed NCT01005329 Phase 2 Carboplatin;Cisplatin;Paclitaxel
14 A Randomized Phase II Trial of Temsirolimus (NCI-Supplied Agent, NSC # 683864) or the Combination of Hormonal Therapy Plus Temsirolimus in Women With Advanced, Persistent, or Recurrent Endometrial Carcinoma Completed NCT00729586 Phase 2 Megestrol Acetate;Tamoxifen Citrate;Temsirolimus
15 A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
16 A Phase II Pilot Investigation Of The Relationship Of Short Term Depo-Provera (Medroxyprogesterone Acetate) Exposure To The Morphologic , Biochemical, And Molecular Changes In Primary Endometroid Adenocarcinoma of the Uterine Corpus Completed NCT00064025 Phase 2 Medroxyprogesterone
17 A Phase 2 Study of Sunitinib Malate in Recurrent or Metastatic Endometrial Carcinoma Completed NCT00478426 Phase 2 Sunitinib Malate
18 A Phase II Evaluation of Trastuzumab (MoAb HER2) in Patients With Advanced, Recurrent or Persistent Endometrial Carcinoma With or Without Prior Chemotherapy Completed NCT00006089 Phase 2
19 A Phase II Evaluation of Copanlisib (BAY 80-6946), a Selective Inhibitor of PI3KCA, in Patients With Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations Completed NCT02728258 Phase 2 Copanlisib
20 Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women With Breast or Gynecologic Cancer Completed NCT03180294 Phase 2 Bupropion 150 mg XL;Placebo
21 A Phase II, Randomized Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (LEE011) in Patients With Advanced or Recurrent Endometrial Carcinoma Recruiting NCT03008408 Phase 2 Everolimus;Letrozole;Ribociclib
22 A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer Recruiting NCT03660826 Phase 2 Capivasertib;Cediranib;Cediranib Maleate;Olaparib
23 Molecular Analysis for Therapy Choice (MATCH) Recruiting NCT02465060 Phase 2 Adavosertib;Afatinib;Afatinib Dimaleate;Binimetinib;Capivasertib;Copanlisib;Copanlisib Hydrochloride;Crizotinib;Dabrafenib;Dabrafenib Mesylate;Dasatinib;Defactinib;Defactinib Hydrochloride;Erdafitinib;FGFR Inhibitor AZD4547;Ipatasertib;Larotrectinib;Larotrectinib Sulfate;Osimertinib;Palbociclib;PI3K-beta Inhibitor GSK2636771;Sapanisertib;Sunitinib Malate;Taselisib;Trametinib;Ulixertinib;Vismodegib
24 A Phase II Study With a Limited Safety Lead-In of Enzalutamide in Combination With Carboplatin and Paclitaxel in Advanced Stage or Recurrent Endometrioid Endometrial Cancer Active, not recruiting NCT02684227 Phase 2 Carboplatin;Enzalutamide;Paclitaxel
25 A Three Arm Randomized Phase II Study of Paclitaxel/Carboplatin/Bevacizumab (NSC #704865), Paclitaxel/Carboplatin/Temsirolimus (NSC #683864) and Ixabepilone (NSC #710428)/Carboplatin/Bevacizumab as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer Active, not recruiting NCT00977574 Phase 2 Carboplatin;Ixabepilone;Paclitaxel;Temsirolimus
26 Step Into Wellness: A Program of Health and Recovery for Endometrial Cancer Survivors Active, not recruiting NCT03367923 Phase 2
27 A Phase 2 Study of XL184 (Cabozantinib) in Recurrent or Metastatic Endometrial Cancer Active, not recruiting NCT01935934 Phase 2 Cabozantinib S-malate
28 A Phase II Study of the Levonorgestrel Intrauterine Device (Mirena) to Treat Complex Atypical Hyperplasia and Grade 1 Endometrioid Endometrial Carcinoma Active, not recruiting NCT00788671 Phase 2
29 A Randomized Phase 2 Study of Cabozantinib in Combination With Nivolumab in Advanced, Recurrent Metastatic Endometrial Cancer Active, not recruiting NCT03367741 Phase 2 Cabozantinib S-malate
30 A Phase Ib Study of the Oral PARP Inhibitor Olaparib With the Oral mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial, Triple Negative Breast, and Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT02208375 Phase 1, Phase 2 Capivasertib;Olaparib;Vistusertib
31 A Phase II Study of Tazemetostat (EPZ-6438) (IND # 138671) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma Active, not recruiting NCT03348631 Phase 2 Tazemetostat
32 A Phase II Trial of DCTD-Sponsored Dasatinib in Recurrent/Persistent Ovary, Fallopian Tube, Primary Peritoneal, and Endometrial Clear Cell Carcinoma Characterized for the Retention or Loss of BAF250a Expression Active, not recruiting NCT02059265 Phase 2 Dasatinib
33 A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus Active, not recruiting NCT00492778 Phase 2 Cisplatin
34 A Phase II Study of Metformin in Combination With Doxycycline in Patients With Localized Breast, and Uterine, and Cervical Cancer Active, not recruiting NCT02874430 Phase 2 Metformin Hydrochloride;Doxycycline
35 A Phase IB and Randomized Phase II Trial of Megestrol Acetate With or Without Ipatasertib in Recurrent or Metastatic Endometrioid Endometrial Cancer Not yet recruiting NCT05538897 Phase 1, Phase 2 Ipatasertib;Megestrol Acetate
36 A Pilot Phase II Trial of Radiation Therapy "Sandwiched" Between Paclitaxel and Carboplatin in Patients With High-Risk Endometrial Cancer After Standard Surgical Staging Terminated NCT01041027 Phase 2 Paclitaxel;Carboplatin
37 A Pilot Phase II Trial of Intravenous Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation in Patients With Advanced Stage Uterine Serous Carcinoma Terminated NCT02112552 Phase 2 Paclitaxel;Carboplatin
38 A Randomized Phase II Evaluation of Continuous Progestin Therapy vs. Sequential Progestin Therapy in the Treatment of Endometrial Intraepithelial Neoplasia (EIN) From a Referred Cohort of Atypical Endometrial Hyperplasia (AEH) or EIN Patients That Desire Uterine Preservation Terminated NCT00503581 Phase 2 Megestrol Acetate
39 A Phase I Clinical Trial of mTOR Inhibition With Rapamycin for Enhancing Intranodal Dendritic Cell Vaccine Induced Anti-tumor Immunity in Patients With NY-ESO-1 Expressing Solid Tumors Completed NCT01522820 Phase 1 Sirolimus
40 Pilot and Translational Study of Dasatinib (NSC#732517) Paclitaxel and Carboplatin in Women With Advanced Stage and Recurrent Endometrial Cancer Completed NCT01440998 Phase 1 Carboplatin;Dasatinib;Paclitaxel
41 A Phase I Study of IV Doxorubicin Plus Intraperitoneal (IP) Paclitaxel and IV or IP Cisplatin in Endometrial Cancer Patients at High Risk for Peritoneal Failure Completed NCT00575952 Phase 1 Cisplatin;Doxorubicin Hydrochloride;Paclitaxel
42 A Phase I Study of Halichondrin B Analog E7389 in Combination With Gemcitabine in Patients With Refractory or Advanced Solid Tumors Completed NCT00410553 Phase 1 Eribulin Mesylate;Gemcitabine Hydrochloride
43 Phase I Trial of the Treatment of Advanced Endometrial Cancer With Concurrent Weekly Paclitaxel and Cisplatin and Whole Abdominal Radiation Therapy Completed NCT00005840 Phase 1 Paclitaxel;Cisplatin
44 Phase I Toxicity Trial of Doxorubicin-Cisplatin Followed by Whole Abdominal Irradiation for Advanced Endometrial Carcinoma Completed NCT00005830 Phase 1 Doxorubicin Hydrochloride;Cisplatin
45 A Randomized Phase I Study With a Safety Lead-In to Assess the Antitumor Efficacy of the MEK Inhibitor Trametinib Alone or in Combination With GSK2141795, an AKT Inhibitor, in Patients With Recurrent or Persistent Endometrial Cancer NCT #01935973 Completed NCT01935973 Phase 1 Trametinib;Uprosertib
46 Phase 1/1B Study of DS-8201a in Combination With ATR Inhibition (AZD6738) in Advanced Solid Tumors With HER2 Expression (DASH Trial) Recruiting NCT04704661 Phase 1 Ceralasertib
47 A Phase I Pilot Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA) Recruiting NCT05269381 Phase 1 Cyclophosphamide
48 Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib, or With Atezolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax Recruiting NCT05092373 Phase 1 Cabozantinib S-malate;Nab-paclitaxel
49 A Phase 1 Open-Label, Dose-Escalation and Dose-Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Anti-Tumor Activity of IACS-6274 as Monotherapy and in Combination in Patients With Advanced Solid Tumors Recruiting NCT05039801 Phase 1 Glutaminase Inhibitor IPN60090;Bevacizumab;Paclitaxel
50 Safety and Efficacy of Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Ovarian, Uterine, Appendiceal, Colorectal, and Gastric Cancer Patients With Peritoneal Carcinomatosis (PC) Recruiting NCT04329494 Phase 1 Cisplatin;Doxorubicin;Fluorouracil;Irinotecan;Leucovorin;Mitomycin;Oxaliplatin

Search NIH Clinical Center for Uterine Corpus Cancer

Genetic Tests for Uterine Corpus Cancer

Anatomical Context for Uterine Corpus Cancer

Organs/tissues related to Uterine Corpus Cancer:

FMA: Uterine Corpus
MalaCards : Breast, Ovary, Cervix, Prostate, Endothelial, Liver, Lymph Node

Publications for Uterine Corpus Cancer

Articles related to Uterine Corpus Cancer:

(show top 50) (show all 262)
# Title Authors PMID Year
1
Enhanced Recovery after Uterine Corpus Cancer Surgery: A 10 Year Retrospective Cohort Study of Robotic Surgery in an NHS Cancer Centre. 62
36358881 2022
2
Temporal trends and factors associated with the cancer diagnosed at stage IV in patients included in the integrated hospital-based cancer registry system in Brazil in two decades. 62
36087358 2022
3
Development of healthy lifestyle consciousness index for gynecological cancer patients. 62
35674795 2022
4
COX2 Effects on endometrial carcinomas progression. 62
36049440 2022
5
Long-term risk of uterine malignancies in women with uterine fibroids confirmed by myomectomy: a population-based study. 62
35775461 2022
6
Cancer incidence and mortality in Poland in 2019. 62
35760845 2022
7
Racial and Ethnic Differences in Hysterectomy-Corrected Uterine Corpus Cancer Mortality by Stage and Histologic Subtype. 62
35511145 2022
8
Completeness and selection bias of a Belgian multidisciplinary, registration-based study on the EFFectiveness and quality of Endometrial Cancer Treatment (EFFECT). 62
35650593 2022
9
Disseminated Primary Uterine Hepatoid Adenocarcinoma with α-Fetoprotein Production Demonstrated on 18F-FDG PET/CT. 62
35741257 2022
10
Major clinical research advances in gynecologic cancer in 2021. 62
35245004 2022
11
Associations of genetic susceptibility to 16 cancers with risk of breast cancer overall and by intrinsic subtypes. 62
35047862 2022
12
Trends in Incidence and Mortality of Gynecological and Breast Cancers in Poland (1980-2018). 62
35115839 2022
13
Excess risk of subsequent malignant neoplasms in adolescent and young adult cancer survivors: Results from the first Italian population-based cohort. 62
34582036 2022
14
Improved long-term survival of corpus cancer in Japan: A 40-year population-based analysis. 62
34494658 2022
15
Risk and prognosis of second corpus uteri cancer after radiation therapy for pelvic cancer: A population-based analysis. 62
36249002 2022
16
Risks of subsequent primary cancers among breast cancer survivors according to hormone receptor status. 62
34002851 2021
17
Body composition and risk of major gynecologic malignancies: Results from the UK Biobank prospective cohort. 62
34114748 2021
18
Major clinical research advances in gynecologic cancer in 2020. 62
34085794 2021
19
Association of laboratorial parameters and prognostic factors in uterine corpus cancer. 62
34550258 2021
20
Trends in hysterectomy-corrected uterine cancer mortality rates during 2002 to 2015: mortality of nonendometrioid cancer on the rise? 62
32683690 2021
21
A national surveillance study of the current status of reirradiation using brachytherapy in Japan. 62
32888854 2021
22
Body mass index and waist circumference in relation to the risk of 26 types of cancer: a prospective cohort study of 3.5 million adults in Spain. 62
33441148 2021
23
[Incidence and mortality of corpus uteri cancer in China, 2015]. 62
33472322 2021
24
Age-specific corpus uteri cancer incidence rate in the world. 62
33089865 2020
25
Years of life lost due to premature death and their trends in people with malignant neoplasm of female genital organs in Shanghai, China during 1995-2018: a population based study. 62
33004024 2020
26
Clinical and histopathologic analysis of gynecological cancer: a single institute experience over 7 years. 62
32131080 2020
27
Trends in Mortality Rates of Corpus Uteri and Ovarian Cancer in Lithuania, 1987-2016. 62
32668695 2020
28
National and Subnational Trends of Incidence and Mortality of Female Genital Cancers in Iran; 1990-2016. 62
32657594 2020
29
Major clinical research advances in gynecologic cancer in 2019. 62
32319232 2020
30
Hyaluronic acid gel injection in rectovaginal septum reduced incidence of rectal bleeding in brachytherapy for gynecological malignancies. 62
31879238 2020
31
Investigating the Nexus between Gynaecologic Cancer and Human Development Index. 62
32358937 2020
32
Association between the incidence and mortality rates for corpus uteri cancer and human development index (HDI): a global ecological study. 62
32206653 2020
33
Impact of maternal reproductive factors on cancer risks of offspring: A systematic review and meta-analysis of cohort studies. 62
32226046 2020
34
Mortality prediction in women with corpus uteri cancer in Brazil: a 21-year analysis. 62
32419841 2020
35
Increasing incidence and survival of corpus uteri cancer in Estonia over the past two decades. 62
31326850 2019
36
Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: Multicenter, open-label phase 2 trial. 62
31348579 2019
37
Hysterectomy-Corrected Uterine Corpus Cancer Incidence Trends and Differences in Relative Survival Reveal Racial Disparities and Rising Rates of Nonendometrioid Cancers. 62
31116674 2019
38
Beyond Obesity: The Rising Incidence and Mortality Rates of Uterine Corpus Cancer. 62
31232669 2019
39
Vitamin D levels and cancer incidence in 217,244 individuals from primary health care in Denmark. 62
30613979 2019
40
Prevalence, characteristics, and risk factors of occult uterine cancer in presumed benign hysterectomy. 62
30853364 2019
41
Incidence and mortality of corpus uteri cancer in China, 2008-2012. 62
31354212 2019
42
Overweight in midlife and risk of cancer in late life: A nationwide Swedish twin study. 62
30565668 2019
43
A proposal for updating the staging of endometrial cancer. 62
30776091 2019
44
Mistletoe in oncological treatment: a systematic review : Part 2: quality of life and toxicity of cancer treatment. 62
30673872 2019
45
Mistletoe in oncological treatment: a systematic review : Part 1: survival and safety. 62
30673873 2019
46
Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry. 62
30733056 2019
47
The EMPCAN study: protocol of a population-based cohort study on the evolution of the socio-economic position of workers with cancer. 62
30937166 2019
48
Risk of subsequent myeloid neoplasms after radiotherapy treatment for a solid cancer among adults in the United States, 2000-2014. 62
29795414 2018
49
Secondary Breast, Ovarian, and Uterine Cancers After Colorectal Cancer: A Nationwide Population-Based Cohort Study in Korea. 62
30239394 2018
50
Advancing Uterine Cancer Survivorship Among African American Women. 62
30126566 2018

Variations for Uterine Corpus Cancer

Copy number variations for Uterine Corpus Cancer from CNVD:

6
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 162862 22 22706138 22714284 Decreasing copy number GSTT1 Corpus uteri cancer

Expression for Uterine Corpus Cancer

Search GEO for disease gene expression data for Uterine Corpus Cancer.

Pathways for Uterine Corpus Cancer

Pathways related to Uterine Corpus Cancer according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.58 TP53 PTEN PIK3CA HRAS ERBB2
2
Show member pathways
12.39 TP53 PIK3CA HRAS ERBB2
3
Show member pathways
12.33 TP53 PIK3CA HRAS ERBB2
4
Show member pathways
12.23 ERBB2 HRAS PIK3CA PTEN TP53
5
Show member pathways
12.2 ERBB2 HRAS PIK3CA PTEN TP53
6 12.17 PTEN PIK3CA HRAS ERBB2
7
Show member pathways
12.12 TP53 PTEN PIK3CA HRAS
8
Show member pathways
12.04 TP53 PTEN PIK3CA HRAS ERBB2
9
Show member pathways
12.02 TP53 PTEN PIK3CA HRAS
10
Show member pathways
11.98 ERBB2 HRAS PIK3CA PTEN
11 11.83 TP53 PTEN HRAS
12 11.78 TP53 PTEN PIK3CA
13
Show member pathways
11.78 PTEN PIK3CA HRAS ERBB2
14 11.71 TP53 PIK3CA HRAS
15
Show member pathways
11.68 TP53 PIK3CA HRAS
16 11.64 TP53 PTEN PPP2R1A
17 11.6 PTEN MIR34C MIR34B MIR200C
18 11.57 HRAS PIK3CA PTEN
19 11.56 TP53 PTEN PIK3CA HRAS ERBB2
20
Show member pathways
11.51 TP53 PTEN PIK3CA
21 11.38 TP53 MIR34C MIR34B MIR3074
22 11.3 TP53 HRAS ERBB2
23 11.24 PIK3CA HRAS ERBB2
24 11.22 TP53 PTEN PIK3CA HRAS ERBB2
25 11.13 PTEN PIK3CA HRAS
26 10.89 TP53 PTEN PIK3CA HRAS ERBB2 ARID1A

GO Terms for Uterine Corpus Cancer

Biological processes related to Uterine Corpus Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 phosphatidylinositol 3-kinase signaling GO:0014065 9.73 PTEN PIK3CA ERBB2
2 miRNA-mediated gene silencing GO:0035195 9.73 MIR34C MIR34B MIR3074 MIR200C MIR139 MIR10B
3 positive regulation of connective tissue replacement GO:1905205 9.32 MIR34C MIR34B
4 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.16 MIR34C MIR34B
5 negative regulation of protein kinase B signaling GO:0051898 9.02 PTEN MIR34C MIR34B MIR200C

Molecular functions related to Uterine Corpus Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA base-pairing translational repressor activity GO:1903231 9.43 MIR34C MIR34B MIR200C MIR139 MIR10B MIR101-1
2 mRNA 3'-UTR binding GO:0003730 9.23 TP53 MIR34C MIR34B MIR200C MIR139 MIR10B

Sources for Uterine Corpus Cancer

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....